On July 15, 2023, the fourth stop of the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022) Interpretation Meeting and Rocaltrol® City Tour” jointly organized by Pharmanovia & Hesena was successfully held at the Hangzhou Friendship Hotel. The original intention of the “City Tour” activity is to enhance the guiding role of the “Guidelines” for clinicians and promote the whole society to pay attention to the prevention and treatment of osteoporosis. We hope to use this activity to assist the Osteoporosis and Bone Mineral Disease Branch of the Chinese Medical Association to jointly Promote the standardized diagnosis and treatment of osteoporosis, strengthen the linkage between hospitals and doctors at all levels, and improve the treatment and rehabilitation of osteoporotic fractures.
The meeting agenda was set around the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022), and Professor Li Weixu, chairman of the Professional Committee of Osteoporosis and Bone Mineral Diseases of Zhejiang Medical Association, and the director-designate of Zhejiang Professional Committee of Osteoporosis were invited Committee member Professor Yang Lei and two professors presided over the meeting, and three speakers with rich clinical experience gave you a detailed introduction to the relevant content of the diagnosis and treatment in the new version of the guideline, highlighting the sharing of the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” ( 2022) updated content, sorting out the important role of Rocaltrol in the field of osteoporosis. At the same time, eight experts in the field of osteoporosis communicated with each other in the meeting, sharing hot information and treatment concepts of osteoporosis treatment. It fully embodies the purpose of “city meeting” to build a communication platform for doctors and promote the linkage between departments and hospitals.
After the meeting started, Professor Li Weixu first thanked all the participants for attending the meeting in spite of their busy schedules, and also thanked Pharmanovia & Hesenna for their continuous attention to the field of osteoporosis treatment. At the same time, he mentioned that Hesenna is a local pharmaceutical company in Zhejiang. Then, Professor Ying Qifeng from Zhejiang Provincial People’s Hospital was invited to introduce the diagnosis and differential diagnosis of osteoporosis to the participating experts. Through the wonderful sharing of the guidelines, he pointed out the updated content, which provided a lot of diagnosis and differential diagnosis for the doctors present. New ideas for diagnosis. It is also proposed that patients with low back pain, general pain, hyperthyroidism, hyperparathyroidism, diabetes and other diseases should do bone density screening as soon as possible, and seek medical treatment as soon as possible if problems are found. After the content, three experts, Prof. Chen Jianming from the Sixth Hospital of Ningbo, Prof. Shi Xiaolin from the Second Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine, and Prof. Xu Sanzhong from the First Affiliated Hospital of Zhejiang University School of Medicine, conducted a discussion. It is necessary to carefully inquire about the basic situation of the patients before taking the medicine, and they are very good about the hierarchical management of the new version of the guidelines. For young doctors, you can compare the changes between the previous guidelines and the new version.
The second topic of the meeting was Professor Hong Dun, member of the Standing Committee of Zhejiang Osteoporosis and Osteopathy Branch and vice president of Taizhou Hospital Orthopedics Branch. Professor Hong Dun gave an in-depth introduction to the main drugs for the prevention and treatment of osteoporosis. In particular, the effect of active vitamin D (Rocaltrol) on bone density was mentioned when supplementing the basic bone health supplement vitamin D in the basic measures. The safety of active vitamin D (Rocaltrol) has also been approved, and it can improve muscle strength and reduce the risk of falls. After the content, three experts, Professor Bian Pingda from Zhejiang Provincial People’s Hospital, Professor Wan Shuanglin from Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, and Professor Fei Jun from Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, conducted discussions. Patients need to have certain outdoor activities during the treatment period. Patient compliance with drug treatment is very important. At the same time, regular monitoring is required. Doctors must do a good job in patient education.
The third topic is the deputy chairman of the third Zhejiang Medical Association Osteoporosis and Bone Mineral Disease Branch, the executive deputy director of the Ningbo Osteoporosis Prevention and Treatment Clinical Guidance Center, and the Chinese Osteoporosis Expert Committee of the International Bone Densitometry Society Professor Fei Jinping of Ningbo Huamei Hospital, University of Chinese Academy of Sciences, as an expert in nephrology, mentioned that Rocaltrol is very safe and effective, with a wide range of indications, and is recommended by multinational guidelines. Osteoporosis caused by rheumatic immune diseases should be treated as early as possible. After the session, two experts, Professor Qiu Xiaohui from Li Huili Hospital of Ningbo Medical Center and Professor Zhao Xiaofeng from Shaoxing People’s Hospital, had a discussion.
The last content is the introduction of the Linglong AI Bone Densitometer by Hesenna Company, and at the same time, the engineer of the instrument was invited to give guidance. After the meeting, Prof. Fei Jinping, Prof. Ying Qifeng, and Prof. Wan Shuanglin tested the bone density together, saying that the detection speed is very fast.
Professor Yang Lei presided over the final discussion session. Many experts discussed the problems encountered in their clinical practice. Professor Yang Lei once again emphasized that Rocaltrol(calcitriol ) capsules are an indispensable therapeutic drug in the treatment of osteoporosis . It is widely used in orthopedics, endocrinology, nephrology, geriatrics, rheumatology, etc. It is of German quality and has been on the market in China for 30 years.
On June 18, 2023, the third stop of the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022) Interpretation Meeting and Rocaltrol® City Tour” co-sponsored by Pharmanovia & Hessina was successfully held in Fuzhou Grand Hotel. The establishment of Rocaltrol ® City Tour Project aims to enhance the guiding role of the “Guidelines” for clinicians through the form of city tours, and combine the latest clinical experience and methods in the standardized diagnosis and treatment of osteoporosis to help people at all levels The hospital improves the standardized diagnosis and treatment of osteoporosis and patient management, and hopes to take this opportunity to learn, exchange, and discuss together, so as to maximize its social responsibility of fighting osteoporosis, serving the clinic, and benefiting patients.
Professor Yan Sunjie , Chairman of the conference, director of the Department of Endocrinology, the First Affiliated Hospital of Fujian Medical University
Professor Yan first thanked everyone for participating in this meeting. Fuzhou is the third stop of the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022) Interpretation Meeting and Rocaltrol® City Tour”, which illustrates the importance of osteoporosis in Fujian Province. The emphasis on diagnosis and treatment and being at the forefront of the field of osteoporosis also hope that more clinicians and researchers can better understand the new progress, new guidelines and new evidence-based medical evidence in the field of osteoporosis diagnosis and treatment through the interpretation. The power of multiple disciplines such as clinic and laboratory will jointly empower the standardized diagnosis and treatment of osteoporosis in Fujian Province.”
Professor Shi Xiulin , Conference Speaker Deputy Director of Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University
As the first speaker of this conference, Professor Shi Xiulin shared the diagnosis and differential diagnosis of osteoporosis. Professor Shi introduced the diagnostic criteria of the new version of the guidelines, combined with nearly ten clinical cases in the department, provided many new ideas for diagnosis and differential diagnosis to the doctors present, and pointed out six unusual differential diagnoses: unusual bone pain, unusual Unusual age, unusual level of bone turnover, unusual treatment response, unusual course of disease, and unusual family history.
Professor Cai Siqing , Conference Speaker Administrative Director, Department of Radiology, The Second Affiliated Hospital of Fujian Medical University
As an expert in the Department of Radiology, Professor Cai explained the standard report and misunderstandings of bone density examination from the perspective of imaging. According to the requirements of the new version of the guidelines, he pointed out some wrong terminology, such as the grading of osteoporosis, only low bone mass , Osteoporosis and severe osteoporosis, there is no expression of moderate or severe osteoporosis, and the principle of bone density examination is low, not high, and osteoporosis can be diagnosed if there is a brittle fracture. Professor Cai pointed out that patients with hyperparathyroidism, diabetes and obesity are more suitable for forearm bone density testing. Linglong dual-energy X-ray bone densitometer is small, easy to install and operate, and is quite suitable for screening and use at the grassroots level.
Professor Luo Li , Speaker of the conference, deputy director of the Department of Hypertension, Department of Geriatrics, and the Second Department of Cadres of the First Affiliated Hospital of Fujian Medical University
Finally, Professor Luo Li shared the risks and harms of osteoporotic fractures, anti-osteoporosis drug treatment and the role of Vit D in the treatment of osteoporotic fractures. Professor Luo emphasized that calcitriol (Rocaltrol) does not require the activation of liver and kidney hydroxylation, it can improve bone density in patients with osteoporosis, increase muscle strength in patients with osteoporosis, prevent falls and reduce the incidence of fractures. “Guidelines for Perioperative Intervention of Osteoporotic Fractures” recommends active Vit D as the basic perioperative medication for patients with osteoporotic fractures.
Professor Yan presided over the final discussion session and commented on the meeting. He mentioned that the lecturer’s courseware not only shared guideline updates, but also showed more clinical cases, which I believe will benefit many doctors a lot. During the questioning session, the guests asked the three speakers about the problems they encountered in their clinical work, and the three speakers answered their questions, and the atmosphere of academic exchanges was strong. The participants expressed that they had gained a lot of cutting-edge information related to the diagnosis and treatment of osteoporosis through this meeting, and had a deeper understanding of the diagnosis and treatment of osteoporosis.
On June 13, 2023, the second stop of the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022) Interpretation Meeting and Rocaltrol® City Tour” jointly organized by Pharmanovia & Hesena was held in Lanhai Yuhua, Jinan City, Shandong Province The Grand Hotel was successfully held. The original intention of the “City Tour” activity is to enhance the guiding role of the “Guide” to clinicians and promote the whole society to pay attention to the prevention and treatment of osteoporosis. We hope to use this activity to assist the Osteoporosis and Bone Mineral Disease Branch of the Chinese Medical Association to jointly Promote the standardized diagnosis and treatment of osteoporosis, strengthen the linkage between hospitals and doctors at all levels, and improve the treatment and rehabilitation of osteoporotic fractures.
The meeting agenda was set around the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022), and academic leaders were invited, members of the Osteoporosis and Bone Minerals Branch of the Chinese Medical Association, and directors of the Osteoporosis and Bone Minerals Branch of the Shandong Medical Association Committee member, chairman of the Osteoporosis and Bone Mineral Salt Branch of Shandong Medical Association, Professor Xu Jin from the Department of Endocrinology of Shandong Provincial Hospital presided over the meeting, and three speakers with rich clinical experience introduced the diagnosis and treatment in the new guideline in detail related content, highlighted and shared the updated content of the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022), and sorted out the important role of Rocaltrol in the field of osteoporosis. Experts in the field of osteoporosis communicated with each other in the meeting, and shared hot information and treatment concepts of osteoporosis treatment. It fully embodies the purpose of “city meeting” to build a communication platform for doctors and promote the linkage between departments and hospitals.
After the meeting started, Professor Xu Jin first thanked all the participants for attending the meeting in spite of their busy schedules, and also thanked Pharmanovia & Hesenna for their continuous attention to the field of osteoporosis treatment, and introduced that the prevention and treatment of osteoporosis in my country is facing “one high and three lows”. The serious challenge is that the prevalence rate is high, but the awareness rate, diagnosis rate and treatment rate are low. Therefore, the whole society should pay more attention to the prevention and treatment of osteoporosis, especially graded diagnosis and treatment, bone density screening, early diagnosis, early medication and treatment, especially to prevent refracture after fracture. Then, the speaker, Professor Kong Lei from the Department of Endocrinology, Shandong Provincial Hospital, was invited to introduce the diagnosis and differential diagnosis of osteoporosis to the participating experts. Through the wonderful sharing of the guidelines, he especially pointed out the updated content, which provided many diagnoses for the doctors present. New ideas with differential diagnosis. And put forward diabetics, the elderly due to poor eyesight. Need to pay more attention to walking safety to prevent falls. Bone metabolism indicators are monitored every 2-3 months, and bone density is monitored once every 6-12 months.
The second topic of the meeting was Professor Chen Shihong, the chairman-designate of the Osteoporosis and Bone Mineral Disease Branch of Shandong Medical Association, and the Department of Endocrinology of the Second Hospital of Shandong University. Professor Chen Shihong gave an in-depth introduction to the main drugs for the prevention and treatment of osteoporosis. In particular, the effect of active vitamin D (Rocaltrol) on bone density was mentioned when supplementing the basic bone health supplement vitamin D in the basic measures. The safety of active vitamin D (Rocaltrol) has also been approved, and regular monitoring of blood calcium and urine calcium has been proposed.
Finally, Professor Sun Hongsheng from the Department of Rheumatology and Immunology of Shandong Provincial Hospital combined his own diseases in the Department of Rheumatology and Immunology, such as rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, Sjogren’s syndrome and systemic sclerosis. Active vitamin D (Rocaltrol) plays an important role in the treatment and rehabilitation of patients. At the same time, it is emphasized that patients are expected to use glucocorticoids for more than 3 months, and the dose is greater than 5mg for osteoporosis treatment intervention.
Prof. Xu Jin presided over the final discussion session. Many experts discussed the problems encountered in their clinical practice. Prof. Xu Jin once again emphasized that Rocaltrol(calcitriol) capsules are an indispensable therapeutic drug in the treatment of osteoporosis , It is widely used in sarcopenia, renal bone disease, and secondary osteoporosis. At the same time, Professor Xu Jin also mentioned that more than 20 years ago, diabetes gradually paid more attention to diagnosis and treatment. At present, diabetes diagnosis and treatment have been popularized and greatly improved. Professor Xu strongly appealed to medical staff and all walks of life to pay attention to and pay attention to osteoporosis, so as to improve the bone health of the whole people. Finally, Professor Xu Jin hoped that Pharmanovia & Hesenna would affirm the joint promotion of products, jointly promote the integration of diagnosis and treatment in the field of osteoporosis, and create health management in the whole field of osteoporosis, so as to bring good news to Chinese osteoporosis patients.
On June 7, 2023, the first event of the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis (2022) Interpretation Meeting and Rocaltrol® City Tour” jointly organized by Pharmanovia & Hesena was successfully held in Shanghai San Want Hotel. The original intention of the “City Tour” activity is to enhance the guiding role of the “Guide” to clinicians and promote the whole society to pay attention to the prevention and treatment of osteoporosis. We hope to use this activity to assist the Osteoporosis and Bone Mineral Disease Branch of the Chinese Medical Association to jointly Promote the standardized diagnosis and treatment of osteoporosis, strengthen the linkage between hospitals and doctors at all levels, and improve the treatment and rehabilitation of osteoporotic fractures.
The meeting agenda was set around the “Guidelines for the Diagnosis and Treatment of Primary Osteoporosis” (2022), and Zhang Zhenlin, the leader of the guideline writing group with profound academic attainments and the director of the Osteoporosis and Osteopathy Department of the Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, was invited The professor presided over the meeting, and three speakers with rich clinical experience introduced in detail the relevant content of diagnosis and treatment in the new version of the guidelines, and sorted out the important role of Rocaltrol in the field of osteoporosis. Experts in the field of osteoporosis communicated with each other and shared hot information on osteoporosis treatment, which fully reflected the purpose of the “city meeting” to build a communication platform for doctors and promote the linkage between doctors outside the hospital.
After the meeting started, Professor Zhang Zhenlin first thanked all the participants for attending the meeting in spite of their busy schedules, and also thanked Pharmanovia & Hesenna for their continuous attention to the field of osteoporosis treatment, and introduced the clinical development history of Rocaltrol. Then Dr. Li Shanshan, a specialist in Osteoporosis and Osteopathy from the Sixth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine, was invited to introduce the diagnosis and differential diagnosis of osteoporosis to the participating experts. Through a large number of clinical cases, she shared her work in detail It also pointed out that the smart and compact dual-energy bone densitometer can bring convenience to the screening and diagnosis of osteoporosis, and provided new ideas for osteoporosis diagnosis to the participating experts.
The second topic of the meeting was taught by Professor Yue Hua, Deputy Director of Osteoporosis and Osteopathy Administration and Secretary of the Guideline Writing Group of the Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. Professor Yue Hua conducted an in-depth discussion on the main drugs for the prevention and treatment of osteoporosis In the introduction, the role of active vitamin D (Rocaltrol) on bone density was specifically mentioned when supplementing the basic bone health supplement vitamin D in the basic measures. The bisphosphonate ibandronic acid (Bonviva) among bone resorption inhibitors is also the key to anti-osteoporosis treatment.
Finally, Professor Fu Peiliang, deputy director of joint surgery/orthopedics at the Second Affiliated Hospital of the Naval Military Medical University, combined with a large number of cases encountered in his surgical treatment, pointed out that active vitamin D (Rocaltrol) plays an important role in the quality of surgery, patient treatment and rehabilitation.
Professor Zhang Zhenlin presided over the final discussion session. Many experts discussed the problems encountered in their clinical practice. Finally, Professor Zhang Zhenlin hoped that Pharmanovia & Hesenna would speed up the introduction of monthly oral bisphosphonate tablets (Bonviva) for the Chinese osteoporosis patients bring good news.
From May 23rd to 24th, 2023, the British pharmaceutical company Pharmanovia came to Lishui, known as the “Zhejiang Green Valley”, to conduct a two-day on-site inspection and meetings with Zhejiang Hesenna Medicine Co., Ltd. (Hesenna) .
On the afternoon of May 23, Mr. Chen Wei, the representative of Pharmanovia’s controlling shareholder and the president of Deteng (Shanghai) Investment Consulting Co., Ltd., Mr. Dimitri Pimbert, the general manager of Pharmanovia’s Asia-Pacific region, Mr. Ian McAleer, the general manager of China, and Mr. Xin Huihao, the deputy general manager , Ms. Cui French, Chief Financial Officer, Mr. Huang Rui, Director of Market Access and Strategic Planning, Mr. Lu Xiaoyu, Director of Channels and Marketing, Mr. Gu Tianchao, Director of Supply Chain Management; Mr. Gu Lijun, Chairman of Zhejiang Hesenna Medicine, Ms. Li Shu, General Manager, Gong Gong, Director of BD Mr. Zhi met with Wu Shunze, Deputy Secretary of Lishui Municipal Party Committee and Mayor.
The two parties conducted in-depth exchanges on the cooperation of the Luogai full product supply chain project under Pharmanovia and the Luogai full product China production subcontracting base project in Lishui Economic Development Zone. Liu Zhiwei, member of the party group of Lishui Municipal Government, secretary of the Party Working Committee of the Economic Development Zone, and director of the management committee, attended the meeting. Mayor Wu Shunze, on behalf of the Lishui Municipal Government, said that he would actively coordinate and solve the difficulties encountered in the process of project implementation, and provide assistance for Pharmanovia and The cooperation of Zhejiang Hesenna Medicine Co., Ltd. provides the necessary support!
Subsequently, Pharmanovia and Hesenna, under the guidance of Ms. Sun Haiyan, the deputy general manager of Zhejiang Hesenna Medicine, conducted a field inspection of Hesenna’s constant temperature warehouse, inspected the management of Bangluoli warehouse in detail, and learned that the constant temperature warehouse will be further expanded. To 2,500 square meters, it is expected to accommodate up to 80,000 pieces of Rocaltrol®, so as to ensure the supply to the national Luogaiquan market.
On the morning of May 24th, Ms. Fu Lingxia, Marketing Director of Hesenna, introduced the progress of the Rocaltrol® project to Pharmanovia. Pharmanovia fully affirmed the previous sales performance. Provincial linked network pricing work. Ms. Li Shu, general manager of Zhejiang Hesenna M, hopes that Pharmanovia will pay full attention to the relevant policies of the Chinese market and carry out various preparations in advance to ensure the smooth development of Rocaltrol’s sales in the whole market and the continuous growth of sales!
On the afternoon of May 25, Dimitri Pimbert, General Manager of Pharmanovia Asia Pacific, and his team of 6 people visited Professor Liu Jianmin, Department of Endocrinology and Metabolism, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine. The two sides conducted in-depth discussions on hot issues in the field of osteoporosis treatment; Liu Jianmin The professor hoped that Pharmanovia and Hesena would continue to deepen their efforts in the field of osteoporosis treatment, and provide doctors and patients with better products and more comprehensive integrated diagnosis and treatment solutions. Mr. Dimitri Pimbert thanked Professor Liu for his support and hoped that Professor Liu would continue to participate in our academic activities!
The visit by Pharmanovia gave a better understanding of the work carried out by Hesenna in the Chinese market. The two sides formed a good interaction, and also took this opportunity to enhance mutual trust and establish a more effective communication model for future in-depth cooperation. In the future, both parties We will work closely together to expand our business in the Chinese market!
On April 13, 2023, Pharmanovia and Zhejiang Hesenna Medicine (hereinafter referred to as Hesenna) held a strategic cooperation conference and “Leaping Tiger” project (Rocaltrol) launch ceremony.
Ian McAleer, General Manager of Pharmanovia China, and Mr. Gu, Chairman of Hesenna, signed the strategic cooperation agreement as representatives of both parties. This strategic cooperation release marks a more in-depth cooperation in more disease areas, including: endocrine, cardiovascular, oncology, neurology, etc;
The launch of the ” Leapping Tiger ” project also marks the beginning of the joint promotion of Rocaltrol between the two sides, and Hesenna will upgrade the original marketing team to form a professional marketing team to be fully responsible for the academic promotion of Rocaltrol.
After the release of the signing ceremony, the leaders of both sides made speeches to address:
Mr.McAleer expressed the importance Pharmanovia attaches to the Chinese market and its determination to put down roots in China, and made it clear: “Pharmanovia and Hesenna share the same goal, and the Pharmanovia China team has rich experience in the field. Pharmanovia will have many new products to enter China, and we are looking forward to a bright future together!”
Sean Xin, Deputy General Manager of Pharmanovia China, had high expectations for the ” Leaping Tiger Project” and said, “Pharmanovia and Hesenna have a long history of cooperation, and the cooperation of Leaping Tiger Project is a milestone. By using Rocaltrol as a prying point to create a whole field of health management for osteoporosis, Rocaltrol ‘s sales in China will definitely achieve leapfrog growth for the benefit of more Chinese osteoporosis patients.”
Mr. Gu said “Pharmanovia has provided us with quality products that are competitive in the market, and we have set up a professional promotion team for Rocaltrol, which is an important layout for our company in the strategic transformation stage!
Ms. Li, General Manager of Hesenna, said “These two companies will form a deep cooperation in R&D, production and corporate brand building in the future. We hope that Hesenna and Pharmanovia will draw a blueprint for development together and achieve a new leap in strategic development in the future cooperation!”
The strategic cooperation between Pharmanovia & Hesenna is of far-reaching significance, as both parties will jointly promote the construction of integrated diagnosis and treatment in the field of osteoporosis and create a whole field of health management for osteoporosis, which will help the implementation of “Healthy Bones” in the “Health China 2030 Plan” and benefit more patients.
Based in China and facing the world, HSN is a pharmaceutical group that provides integrated services of Commercialization, supply chain, and brand promotion of foreign high-end patented drugs in China. An emerging strategic partner for your brand.
Copyright © 2024 – Hesenna Medicine All rights reserved.
